OncoMatch/Clinical Trials/NCT07284069
Senicapoc and Perampanel for Newly Diagnosed Glioblastoma
Is NCT07284069 recruiting? Yes, currently enrolling (May 2026). This Early Phase 1 trial studies multiple treatments including senicapoc and Perampanel for glioblastoma.
Treatment: senicapoc · Perampanel — Glioblastoma is the most common and aggressive form of brain cancer in adults. Despite surgery, radiotherapy, and chemotherapy, most patients only live about one year after diagnosis. There is an urgent need for new and better treatments. Recent research has shown that glioblastoma cancer cells communicate with surrounding brain cells through electrical signals that help the tumor grow and resist treatment. Two existing drugs, perampanel (used for epilepsy) and senicapoc (previously tested for blood disorders), may block these harmful signals. Laboratory studies suggest that combining these two drugs could slow tumor growth and make cancer cells more sensitive to standard therapy. The SENIPERA trial will test whether perampanel and senicapoc, alone and in combination, are safe and well tolerated when added to standard treatment for newly diagnosed glioblastoma. The study will also measure how well these drugs reach the brain and tumor, and how they affect tumor biology. The study has two parts: Part A: Tests different doses of senicapoc alone to find the maximum tolerable dose. Part B: Randomly assigns patients to receive either perampanel alone or perampanel together with senicapoc. Participants will all receive standard therapy, including surgery, radiochemotherapy, and adjuvant chemotherapy. During surgery, small samples of tumor and fluid will be collected safely to study how the drugs act in the body and how tumor cells respond. Participants will be closely monitored for side effects and followed with regular clinical visits and MRI scans. The trial will take place at Aarhus University Hospital, Denmark, from February 2026 to November 2028 and will enroll 27-36 adult patients. The study aims to identify safe and biologically active treatment combinations that could be tested in larger trials to improve future glioblastoma care.
Check if I qualifyExtracted eligibility criteria
Cancer type
Glioblastoma
Performance status
WHO 0–2
Prior therapy
Cannot have received: perampanel (perampanel)
Previous treatment with or allergic reaction to perampanel
Cannot have received: senicapoc (senicapoc)
Previous treatment with or allergic reaction to senicapoc
Lab requirements
Blood counts
Coagulopathy (INR > 1.8 or APTT > 57s); Thrombocytopenia (platelet count < 100 x 10^3/μL = 100 x 10^9/L); Neutropenia (ANC < 1.5 x 10^3/μL = 1.5 x 10^9/L); Anemia (Hb < 10 g/L = 6.0 mmol/l) [excluded]
Kidney function
Significant renal impairment (eGFR < 60 mL) [excluded]
Liver function
Significant liver function impairment (ALAT > 210 umol/L for men and > 135 umol/L for women or total bilirubin > 25 umol/L) [excluded]
Significant co-morbidities, i.e. Significant liver function impairment (ALAT > 210 umol/L for men and > 135 umol/L for women or total bilirubin > 25 umol/L); Significant renal impairment (eGFR < 60 mL); Coagulopathy (INR > 1.8 or APTT > 57s); Thrombocytopenia (platelet count < 100 x 10^3/μL = 100 x 10^9/L); Neutropenia (ANC < 1.5 x 10^3/μL = 1.5 x 10^9/L); Anemia (Hb < 10 g/L = 6.0 mmol/l)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify